| Loy, Clement |
| Active, not recruiting | 2 | 252 | Europe, Canada, US, RoW | PTC518, Placebo | PTC Therapeutics, PTC Therapeutics, Inc. | Huntington Disease | 02/25 | 08/25 | | |
NAC-preHD, NCT05509153: A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers |
|
|
| Not yet recruiting | 2 | 160 | RoW | NAC, N-Acetylcysteine, Placebo | Western Sydney Local Health District, Deakin University, Monash University, Royal Perth Hospital, The University of Queensland, University of Sydney, University of Melbourne | Huntington Disease | 11/26 | 05/27 | | |
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease |
|
|
| Completed | 1/2 | 47 | Europe, Canada, RoW | WVE-003 | Wave Life Sciences Ltd. | Huntington Disease | 05/24 | 05/24 | | |
NCT01574053: Enroll -HD: A Prospective Registry Study in a Global Huntington's Disease Cohort |
|
|
| Recruiting | N/A | 35000 | Europe, Canada, US, RoW | | CHDI Foundation, Inc. | Huntington's Disease | 01/62 | 01/62 | | |
| Colman, Peter C |
| Recruiting | 3 | 450 | Europe, RoW | Fenofibrate, Inert lactose placebo | University of Sydney, National Health and Medical Research Council, Australia, Juvenile Diabetes Research Foundation Australia, Mylan Pharmaceuticals Inc | Type 1 Diabetes Mellitus, Diabetic Retinopathy, Diabetic Nephropathies | 12/24 | 12/25 | | |
| Recruiting | N/A | 75000 | Europe, Canada, US, RoW | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 07/25 | 07/25 | | |
| Davis, Stephen |
NCT03385928: STOP-MSU: Stopping Haemorrhage With Tranexamic Acid for Hyperacute Onset Presentation Including Mobile Stroke Units |
|
|
| Completed | 2 | 201 | Europe, RoW | Tranexamic Acid, Normal saline, 0.9%NaCl | Neuroscience Trials Australia, The Florey Institute of Neuroscience and Mental Health | Intracerebral Haemorrhage | 05/23 | 05/23 | | |
| Active, not recruiting | 1 | 28 | US | Glucagon-Like Peptide- 1 (GLP-1) infusion, GLP-1, Placebo Comparator: Saline Infusion, Saline infusion | University of Maryland, Baltimore | Type 2 Diabetes Mellitus | 09/25 | 02/26 | | |
| Recruiting | 1 | 32 | US | Epinephrine, Adrenaline, Saline infusion, Placebo | University of Maryland, Baltimore, Vanderbilt University | Diabetes Complications | 09/25 | 02/26 | | |
| Recruiting | 1 | 60 | US | Placebo Oral Tablet, Fluoxetine, DHEA, dehydroepiandrosterone, Fluoxetine and DHEA, Prozac, dehydroepiandrosterone | University of Maryland, Baltimore | Type 1 Diabetes Mellitus | 09/25 | 12/26 | | |
NCT01672255: Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM) |
|
|
| Recruiting | 1 | 64 | US | Fluoxetine, Prozac, Placebo control | University of Maryland, Baltimore, National Heart, Lung, and Blood Institute (NHLBI) | Type 1 Diabetes, Hypoglycemia Associated Autonomic Failure | 09/25 | 12/26 | | |
| Recruiting | 1 | 32 | US | Glucose clamp | University of Maryland, Baltimore, Vanderbilt University | Hypoglycemia | 09/25 | 12/26 | | |
| Withdrawn | N/A | 176 | US | SmartAlbu | University of Maryland, Baltimore | Diabetes Mellitus | 12/23 | 12/23 | | |
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment |
|
|
| Recruiting | N/A | 240 | RoW | Minimally invasive hematoma evacuation | University of Melbourne | Intra Cerebral Hemorrhage, Stroke | 12/25 | 12/26 | | |
| Withdrawn | N/A | 1500 | US | Standard of Care, University of Maryland Medical System (UMMS) Charles Regional Medical Center (CRMC) Appendix A.1. Transitional Care/Nurse Navigator Program, Policy Number: 9770-001, Enhanced Care | University of Maryland, Baltimore, University of Maryland Medical System | Patient Readmission, Pulmonary Disease, Chronic Obstructive, Heart Failure, Diabetes Mellitus Poor Control, Hypertension, Pneumonia | 09/26 | 09/26 | | |
| Leslie, Kate |
NCT04316013: Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial |
|
|
| Recruiting | 3 | 3500 | US, RoW | Sevoflurane, Propofol, Lidocaine IV | Peter MacCallum Cancer Centre, Australia, National Health and Medical Research Council, Australia, Australian and New Zealand College of Anaesthetists, Victorian Comprehensive Cancer Centre | Colonic Cancer, Rectal Cancer, Non Small Cell Lung Cancer | 12/27 | 06/28 | | |
| Toussaint, Nigel |
NCT06598631: Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease |
|
|
| Terminated | 2 | 8 | Europe, Japan, US, RoW | Volenrelaxin, LY3540378, Placebo | Eli Lilly and Company | Chronic Kidney Disease | 12/24 | 12/24 | | |
PHOSPHATE, NCT03573089: Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease |
|
|
| Recruiting | N/A | 3600 | Europe, Canada, RoW | Liberal phosphate target, Intensive phosphate target | The University of Queensland, National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago | Kidney Failure, Chronic, Hyperphosphatemia | 12/27 | 12/28 | | |
| Goldin, Eran Mr |
| Active, not recruiting | 4 | 50 | Europe, RoW | Darvadstrocel, Alofisel, Cx601 | Takeda, Takeda Development Center Americas, Inc. | Crohn's Disease, Complex Perianal Fistula | 03/26 | 03/26 | | |
| Recruiting | 3 | 612 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 03/25 | 04/25 | | |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Recruiting | 3 | 1050 | Europe, Canada, Japan, US, RoW | ABX464, Obefazimod, Placebo | Abivax S.A. | Ulcerative Colitis | 01/26 | 01/30 | | |
| Recruiting | 3 | 1063 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Ulcerative Colitis | 07/26 | 12/27 | | |
|
NCT03390322: Safety and Initial Performance of the DiaGone Device on Type 2 Diabetes Patients |
|
|
| Completed | N/A | 31 | RoW | DiaGone™ | Digma Medical Ltd. | Diabetes Mellitus, Type 2 | 08/24 | 08/24 | | |
| Contact, Use Central |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
| Recruiting | 3 | 200 | RoW | Patiromer Powder for Oral Suspension (Part A), Placebo (Part B), Patiromer Powder for Orals Suspension (Part B) | Vifor Fresenius Medical Care Renal Pharma, Tigermed Consulting Co., Ltd | Hyperkalemia, Renal Insufficiency, Chronic | 12/25 | 03/26 | | |
NCT04167514: Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone (BMT CTN 1705) |
|
|
| Active, not recruiting | 3 | 136 | US | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor (A1-P1), Placebo | CSL Behring, Blood and Marrow Transplant Clinical Trials Network, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), National Cancer Institute (NCI) | Graft Versus Host Disease (GVHD) | 06/24 | 12/24 | | |
| Active, not recruiting | 3 | 126 | Europe, Japan, US, RoW | human immunoglobulin G, IgPro20, Hizentra, Placebo | CSL Behring, CSL Behring LLC, 1020 First Avenue, King of Prussia, PA 19406 | Dermatomyositis | 05/28 | 05/28 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT05819775: CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema |
|
|
| Active, not recruiting | 3 | 20 | Europe, Canada, US, RoW | CSL312, Garadacimab | CSL Behring | Hereditary Angioedema (HAE) | 11/26 | 11/26 | | |
| Terminated | 3 | 194 | Europe, Canada, US, RoW | Clazakizumab, Physiologic saline solution | CSL Behring, ICON Clinical Research | Antibody-mediated Rejection | 04/24 | 04/24 | | |
NCT06003387: Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs) |
|
|
| Recruiting | 3 | 35 | Canada, US, RoW | CSL222 (AAV5-hFIXco-Padua), Etranacogene dezaparvovec | CSL Behring | Hemophilia B | 10/28 | 10/28 | | |
MODULAATE, NCT03805789 / 2018-000329-29: The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant |
|
|
| Recruiting | 2/3 | 310 | Europe, Japan, US, RoW | Alpha-1 antitrypsin (AAT), Alpha-1 proteinase inhibitor, Placebo | CSL Behring, Commercial/Industry, CSL | Acute-graft-versus-host Disease | 09/25 | 03/27 | | |
NCT05485961: Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis |
|
|
| Recruiting | 2/3 | 2310 | Europe, Canada, Japan, US, RoW | CSL300, Clazakizumab, Placebo | CSL Behring | Atherosclerotic Cardiovascular Disease, End Stage Kidney Disease | 12/28 | 12/28 | | |
NCT01294020 / 2010-020925-42: Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf® |
|
|
| Active, not recruiting | 2 | 81 | Europe, RoW | Tacrolimus, Prograf, FK506, Tacrolimus prolonged release, FK506E, MR4, Advagraf, tacrolimus modified release, Astagraf XL, Graceptor, Prograf XL | Astellas Pharma Europe Ltd. | Intestine Transplantation, Kidney Transplantation, Lung Transplantation, Liver Transplantation, Heart Transplantation | 10/15 | 12/25 | | |
STARBORN-1, NCT05871970: Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age |
|
|
| Recruiting | 2 | 38 | US | TARA-002 | Protara Therapeutics | Lymphatic Malformation | 12/25 | 05/26 | | |
ADVANCED-2, NCT05951179: Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer |
|
|
| Recruiting | 2 | 127 | Canada, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 05/30 | 08/30 | | |
NCT04446000: Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects |
|
|
| Terminated | 1 | 52 | Europe | CSL730, Recombinant trivalent human IgG1 Fc multimer, Placebo | CSL Behring | Immune Complex-mediated Autoimmune Diseases | 03/23 | 03/23 | | |
NCT05653713: Effects of CSL324 in the Lung After Segmental Challenge |
|
|
| Completed | 1 | 40 | Europe | CSL324, Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody (mAb), Placebo | CSL Behring | Healthy Volunteers | 07/23 | 07/23 | | |
NCT04082754: A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers |
|
|
| Completed | 1 | 78 | Europe | Human beta common receptor antagonist monoclonal antibody, CSL311, Placebo | CSL Behring | Asthma | 11/23 | 11/23 | | |
ADVANCED-1, NCT05085990: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) |
|
|
| Completed | 1 | 10 | US | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 09/24 | | |
ADVANCED-1, NCT05085977: Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) |
|
|
| Completed | 1 | 12 | Europe, US, RoW | TARA-002 | Protara Therapeutics | Non-muscle Invasive Bladder Cancer | 09/24 | 10/24 | | |
NCT05937581: First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects |
|
|
| Recruiting | 1 | 60 | RoW | CSL040, Placebo | CSL Behring | Disease Driven by Complement Activation | 04/25 | 04/25 | | |
| Completed | N/A | 80 | Europe, US | | Protara Therapeutics | Intestinal Failure-associated Liver Disease | 06/23 | 06/23 | | |
IX-TEND 4001, NCT06008938: An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B |
|
|
| Recruiting | N/A | 500 | US | HEMGENIX, Etranacogene dezaparvovec, Factor IX (FIX) | CSL Behring | Hemophilia B | 08/43 | 08/43 | | |
| Orr, Carolyn |
NAC-preHD, NCT05509153: A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers |
|
|
| Not yet recruiting | 2 | 160 | RoW | NAC, N-Acetylcysteine, Placebo | Western Sydney Local Health District, Deakin University, Monash University, Royal Perth Hospital, The University of Queensland, University of Sydney, University of Melbourne | Huntington Disease | 11/26 | 05/27 | | |
NCT05032196: Study of WVE-003 in Patients With Huntington's Disease |
|
|
| Completed | 1/2 | 47 | Europe, Canada, RoW | WVE-003 | Wave Life Sciences Ltd. | Huntington Disease | 05/24 | 05/24 | | |
| Ritchie, David |
C-SMART, NCT04534725: COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial; |
|
|
| Completed | 3 | 441 | RoW | Interferon alfa, Selinexor, Lenzilumab | Peter MacCallum Cancer Centre, Australia | Cancer, Covid19, Respiratory Viral Infection | 11/22 | 04/23 | | |
ACTRN12619000581167: Brentuximab Vedotin in combination with donor lymphocyte infusions for Hodgkin lymphoma relapsing or persisting after allogeneic stem cell transplantation |
|
|
| Recruiting | 2 | 10 | | | Melbourne Health, Millenium Pharmaceuticals | Hodgkin lymphoma | | | | |
NIVALLO, NCT03146468: Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation |
|
|
| Active, not recruiting | 2 | 14 | RoW | Nivolumab Injection, Opdivo | Melbourne Health | Haematological Malignancy | 03/22 | 03/22 | | |
ACTRN12620001339943p: REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT)
Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia |
|
|
| Not yet recruiting | 1/2 | 20 | | | The Royal Melbourne Hospital, Maddie Riewoldt's Vision | One of the health conditions being studied in this trial will be Poor Graft Function
; One of the health conditions being studied in this trial will be Aplastic Anaemia | | | | |
ACTRN12620001339943: REscuing bone marrow function in patients with aplaStic anaEmia and bone marrow faiLure post allogEneiC Transplantation (RESELECT)
Phase I/II single arm with historical control study assessing the efficacy and safety of Atorvastatin and N-Acetyl Cysteine in the treatment of Poor Graft Function post allogeneic transplantation and relapsed/refractory aplastic anaemia |
|
|
| Recruiting | 1/2 | 20 | | | The Royal Melbourne Hospital, Maddie Riewoldt's Vision | One of the health conditions being studied in this trial will be Poor Graft Function
, One of the health conditions being studied in this trial will be Aplastic Anaemia | | | | |
ACTRN12617000473369: A clinical trial to evaluate the safety of nivolumab for relapsed or residual haematological cancers after blood or bone marrow transplantation |
|
|
| Active, not recruiting | 1/2 | 14 | | | Melbourne Health, Bristol-Myers Squibb | Haematological malignancies | | | | |
RESELECT2, NCT06607367: REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2 |
|
|
| Not yet recruiting | 1/2 | 20 | RoW | Ruxolitinib (JAKAVI®), Eltrombopag (Revolade®) | Melbourne Health | Poor Graft Function, Aplastic Anemia Idiopathic | 10/25 | 10/26 | | |
ACTRN12619000556145: Maintenance treatment with low-dose lenalidomide after allogeneic stem cell transplantation for patients with acute myeloid leukaemia or myelodysplastic syndrome |
|
|
| Recruiting | 1 | 20 | | | Melbourne Health, Celgene | Acute myeloid leukaemia
, Myelodysplastic syndrome | | | | |
ACTRN12622000308796: Short-course treatment with venetoclax prior to non-myeloablative conditioning allogeneic stem cell transplantation for patients with haematological malignancies. |
|
|
| Recruiting | 1 | 18 | | | Melbourne Health, The Commonwealth of Australia - Medical Research Future Fund (MRFF) | Acute leukaemia (myeloid and/or lymphoid, or biphenotypic), Myelodysplastic syndrome, Chronic lymphocytic leukaemia, B-cell non-Hodgkin lymphoma, Plasma cell myeloma | | | | |
VICTORY, NCT05005299: Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation |
|
|
| Recruiting | 1 | 18 | RoW | Venetoclax, Venclaxta, Fludarabine, Cyclophosphamide | Melbourne Health | Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma | 03/26 | 03/26 | | |
| Christensen, Britt |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
| Kern, Johannes |
| Recruiting | 3 | 1300 | Europe, Canada, Japan, US, RoW | TAK-279 | Takeda | Plaque Psoriasis | 05/26 | 05/26 | | |
NCT06088043: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment |
|
|
| Active, not recruiting | 3 | 693 | Europe, Canada, Japan, US, RoW | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 08/25 | 04/26 | | |
SiroSkin, NCT05860881: Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients |
|
|
| Recruiting | 3 | 146 | RoW | Sirolimus Topical Cream, Rapamycin, Placebo, Vehicle alone | Melanoma and Skin Cancer Trials Limited, Monash University, The University of Queensland | Solid Organ Transplant Recipients, Skin Cancer | 05/26 | 12/26 | | |
| Completed | 2 | 456 | Europe, Japan, US, RoW | Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Systemic Lupus Erythematosus | 11/24 | 11/24 | | |
|
|
NCT06046729: A Study of Eltrekibart (LY3041658) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa |
|
|
| Recruiting | 2 | 350 | Europe, Canada, US, RoW | Eltrekibart, LY3041658, Placebo | Eli Lilly and Company | Hidradenitis Suppurativa | 08/25 | 07/26 | | |
| Campbell, Bruce |
| Completed | 3 | 850 | Europe, Canada, US, RoW | Placebo, Nerinetide, NA-1 | NoNO Inc., University of Calgary | Stroke, Acute | 08/23 | 08/23 | | |
| Recruiting | 3 | 452 | RoW | Tenecteplase, rhTNK-tPA, TNK-tPA, Best Practice (which may include intravenous Alteplase), rt-PA | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 02/26 | 05/26 | | |
TEMPO-2, NCT02398656: A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion |
|
|
| Completed | 3 | 886 | Europe, Canada, RoW | Tenecteplase, TNK-tPA, Antiplatelet treatment, ASA, Clopidogrel | University of Calgary | Stroke, Acute | 01/24 | 04/24 | | |
POST-ETERNAL, NCT05105633: Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke |
|
|
| Recruiting | 2/3 | 688 | RoW | Tenecteplase, Standard Care (which may include intravenous Alteplase) | University of Melbourne | Basilar Artery Occlusion | 08/26 | 12/26 | | |
| Suspended | 2 | 80 | RoW | TBO-309 | The George Institute, Heart Research Institute | Acute Ischemic Stroke | 02/26 | 05/26 | | |
NCT05203224: Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase) |
|
|
| Recruiting | 2 | 300 | RoW | Dornase Alfa, DNase, Pulmozyme | University of Melbourne | Ischemic Stroke | 09/25 | 12/25 | | |
NCT04630353: A Study HB-201 in Patients With Newly Diagnosed HPV16+ Oropharynx or Locally Advanced Cervical Cancer |
|
|
| Terminated | 1 | 10 | US | HB-201 IV | Hookipa Biotech GmbH | HPV 16+ Confirmed Oropharynx Cancer and Cervical Cancer | 11/23 | 11/23 | | |
| Not yet recruiting | N/A | 30 | RoW | Magnetically enhanced diffusion, PULSE Nanomed System | University of Melbourne, Monash University, Euphrates Vascular, Inc. | Ischemic Stroke, Stroke | 12/26 | 03/27 | | |
EVACUATE, NCT04434807: Ultra-Early, Minimally inVAsive intraCerebral Haemorrhage evacUATion Versus Standard trEatment |
|
|
| Recruiting | N/A | 240 | RoW | Minimally invasive hematoma evacuation | University of Melbourne | Intra Cerebral Hemorrhage, Stroke | 12/25 | 12/26 | | |
| Contact, Central |
NCT03641560: A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy |
|
|
| Completed | 4 | 52 | RoW | Enzalutamide, MDV3100, Xtandi, Androgen deprivation therapy (ADT) | Astellas Pharma Inc | Metastatic Castration Resistant Prostate Cancer | 02/24 | 02/24 | | |
| Recruiting | 4 | 30 | US | IgPro10, Privigen | CSL Behring | Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) | 12/29 | 12/29 | | |
NCT02294461: An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants |
|
|
| Completed | 3 | 395 | RoW | Enzalutamide, Xtandi, MDV3100, Placebo | Astellas Pharma Inc | Progressive Metastatic Prostate Cancer | 09/15 | 07/24 | | |
NCT06524739: Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS |
|
|
| Recruiting | 3 | 177 | Canada, US | IgPro20, HIZENTRA®, Placebo | CSL Behring | Post-COVID Postural Orthostatic Tachycardia Syndrome | 09/27 | 09/27 | | |
NCT06617897: Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery |
|
|
| Recruiting | 3 | 90 | Europe | CSL511 Fibrinogen concentrate (human), Cryoprecipitate | CSL Behring | Acquired Fibrinogen Deficiency | 09/26 | 10/26 | | |
TAP, NCT05568888: Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( Study ) |
|
|
| Terminated | 3 | 1370 | Europe, US, RoW | BE1116, 4-Factor Prothrombin Complex, Kcentra®, Beriplex®, Placebo | CSL Behring | Traumatic Injury | 10/24 | 10/24 | | |
NCT02439268: The Safety and Efficacy Study of Vemurafenib (CT) Compared With Vemurafenib (Zelbolaf®) in Advanced Patients Harboring the V600 BRAF Mutation |
|
|
| Active, not recruiting | 2 | 100 | RoW | Vemurafenib, Zelboraf, Vemurafenib (CT), RO5185426, PLX4032 | Cancer Centre of Monoclonal Therapy, LLC, The European Association for Cancer Research, Melanoma Research Foundation, Alliance for Clinical Trials in Oncology in EU | Colorectal Cancer, Recurrent/Refractory BRAFV600E-mutant Gliomas, Advanced Cancers, Melanoma, Advanced BRAF-mutant Cancers | 07/15 | 05/18 | | |
NCT02430220: The Safety and Efficacy Study of Regorafenib (CT) Compared With Regorafenib (STIVARGA) in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 152 | RoW | Regorafenib (CT), BAY 73-4506, Regorafenib (STIVARGA) | Cancer Centre of Monoclonal Therapy, LLC, Clinical Cancer Hospital, Bayer | Solid Tumors, Colorectal Cancer | 04/18 | 09/18 | | |
| Active, not recruiting | 2 | 100 | US | ALG-055009, Placebo | Aligos Therapeutics | NASH, MASH, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis | 11/24 | 12/24 | | |
NCT06545916: Study of Sunobinop on Alcohol Consumption in Alcohol Use Disorder |
|
|
| Recruiting | 2 | 200 | US | Sunobinop, V117957, Placebo to match sunobinop | Imbrium Therapeutics, Purdue Pharma LP | Alcohol Use Disorder | 07/25 | 07/25 | | |
NCT06285214: Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome |
|
|
| Active, not recruiting | 1 | 44 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Interstitial Cystitis/Bladder Pain Syndrome | 06/26 | 06/26 | | |
NCT04285827: Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease |
|
|
| Completed | 1 | 28 | Europe, US | CSL889 | CSL Behring | Sickle Cell Disease | 07/23 | 07/23 | | |
NCT03426254: Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors |
|
|
| Withdrawn | 1 | 10 | RoW | Injections Subcutaneously Talazoparib, MDV3800, BMN673, Oral capsules Talazoparib | Center Trials & Treatment, BioGene Pharmaceutical | Advanced or Recurrent Solid Tumors, Breast Neoplasm | 12/23 | 01/24 | | |
|
| Recruiting | 1 | 174 | US | PRL-02 injection, prednisone, dexamethasone, enzalutamide | Astellas Pharma Global Development, Inc. | Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer | 08/25 | 05/29 | | |
NCT06364696: A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors |
|
|
| Recruiting | 1 | 175 | US | ASP4396 | Astellas Pharma Inc | Solid Tumor | 04/27 | 04/27 | | |
| Recruiting | 1 | 229 | US | ASP1012, Pembrolizumab | Astellas Pharma Global Development, Inc. | Solid Tumor | 06/29 | 06/29 | | |
NCT06248086: A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas |
|
|
| Terminated | 1 | 1 | RoW | ASP2802, MACT, MA-20, ASP101G, MicAbody | Astellas Pharma Global Development, Inc. | B-cell Lymphoma | 12/24 | 12/24 | | |
NCT06024642: Study of V117957 in Overactive Bladder Syndrome |
|
|
| Completed | 1 | 51 | US | V117957, Placebo | Imbrium Therapeutics, Purdue Pharma LP | Overactive Bladder Syndrome | 05/24 | 05/24 | | |
| Completed | N/A | 1443 | US | | Shire | Hunter Syndrome | 02/23 | 02/23 | | |
NCT05104840: A Randomized Study to Determine the Expression of the Furin Protein in Patients With SARS-CoV-2 and Vaccinated Against Coronavirus |
|
|
| Terminated | N/A | 2432 | US, RoW | | Center Trials & Treatment, Oleg Martynenko | COVID-19, SARS-CoV-2, Furin, RGMc Processing, Paired Basic Amino Acid Cleaving Enzyme (PACE) | 03/23 | 03/23 | | |
| Recruiting | N/A | 1257 | US | | Shire | Gaucher Disease | 09/25 | 09/25 | | |
NCT06734585: Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant |
|
|
| Not yet recruiting | N/A | 200 | NA | Gilteritinib, ASP2215, XOSPATA® | Astellas Pharma Singapore Pte. Ltd. | Acute Myeloid Leukemia | 06/25 | 06/25 | | |
OPTION-VMS, NCT06049797: A Study Following Women in Menopause Treated With a Non-hormonal Therapy for Hot Flashes and Night Sweats |
|
|
| Recruiting | N/A | 1000 | US | Fezolinetant, ESN364, VEOZAH, Paroxetine, Citalopram, Escitalopram, Desvenlafaxine, Venlafaxine, Gabapentin, Clonidine, Pregabalin, Oxybutynin, Any other SSRI/SNRI not already specified, Any other non-hormonal pharmacologic therapy prescribed for the treatment of VMS not included in a category above | Astellas Pharma Global Development, Inc. | Hot Flashes | 02/26 | 11/26 | | |
NCT03971253: Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis |
|
|
| Recruiting | N/A | 3000 | Japan | Peficitinib, ASP015K, Smyraf | Astellas Pharma Inc | Rheumatoid Arthritis (RA) | 12/25 | 12/25 | | |
NCT05886348: The Evaluation of Safety and Myopia Progression Control Using Novel Spectacle Lens |
|
|
| Active, not recruiting | N/A | 249 | RoW | Model-A Novel spectacle lens, Model-B Novel spectacle lens, Single vision spectacle lens | HOYA Lens Thailand LTD. | Myopia | 05/26 | 05/27 | | |
NCT06011954: A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection |
|
|
| Recruiting | N/A | 202 | RoW | Enfortumab Vedotin, PADCEV, ASG-22CE | Astellas Pharma Korea, Inc., Seagen Inc. | Urothelial Cancer | 07/27 | 07/27 | | |
| Recruiting | N/A | 350 | US | Veye Lung nodules | Aidence | Lung; Node | 07/21 | 07/21 | | |
| Tang, Wen |
| Recruiting | 3 | 778 | Europe, Canada, Japan, US, RoW | Mirikizumab, LY3074828 | Eli Lilly and Company | Crohn's Disease | 11/24 | 12/26 | | |
